MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39467) - R2 - Effective August 7, 2025

Date Posted: August 7, 2025

This MolDX Local Coverage Determination (LCD) has been revised under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: August 7, 2025

Summary of Changes:

Updated to remove Related National Coverage Document 90.2 – Next Generation Sequencing (NGS). This was added in error. This is effective 8/7/25.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCD or access it via the CMS Medicare Coverage Database (MCD).

Last Updated Aug 07 , 2025